Wedbush raised the firm’s price target on Fate Therapeutics to $7 from $3 and keeps a Neutral rating on the shares following Q4/2023 financial results. The company continues to advance its portfolio of iPSC-derived cellular immunotherapies for patients with cancer and autoimmune disorders, the firm says. Wedbush views a main driver for Fate’s shares to be FT819, an off-the-shelf CAR T-cell that includes a novel CD19-targeted 1XX CAR design.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FATE:
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Fate Therapeutics Inc (FATE) Q4 Earnings Cheat Sheet
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
